Augmentation therapy with human alpha-1-proteinase inhibitor reduces exacerbations in patient with bronchiectasis and alpha-1-antitrypsin deficiency

Augmentation therapy with human alpha-1-proteinase inhibitor reduces exacerbations in patient with bronchiectasis and alpha-1-antitrypsin deficiency

Alpha-1-antitrypsin deficiency (AATD) is a rare cause of noncystic fibrosis (CF) bronchiectasis. The benefits of augmentation therapy in patients with chronic obstructive pulmonary disease (COPD) and pulmonary emphysema are well established. The role of augmentation therapy in AATD bronchiectasis in...

Full description

Bibliographic Details
Main Authors: Emanuel Buck, Maria Ada Presotto, Judith Brock, Kai Schlamp, Martina Veith, Felix J.F. Herth, Franziska Christina Trudzinski
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Alpha-1-antitrypsin
(AATD)
Alpha-1-antitrypsin deficiency
Bronchiectasis
Augmentation therapy
AAT
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007122001629

Internet

http://www.sciencedirect.com/science/article/pii/S2213007122001629

Similar Items